07:27 AM EDT, 07/02/2025 (MT Newswires) -- HLS Therapeutics ( HLTRF ) on Wednesday said Vascepa will now be reimbursed by the Nova Scotia Provincial Drug Plan.

Vascepa will be reimbursed for the secondary prevention of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides, a statement said.

"The PLA [product listing agreement] with Nova Scotia Pharmacare will significantly improve access and reimbursement for Vascepa in Atlantic Canada," said Chief Executive Craig Millian. "This milestone, combined with the recent in-licensing of two new products into our cardiovascular portfolio, supports our efforts to position HLS as a leading Canadian-based company focused on reducing cardiovascular risk for Canadians."

Vascepa is available to over 95% of eligible patients covered by public plans and private insurance in Canada.